Safety and Efficacy of Regional Citrate Anticoagulation in Continuous Blood Purification Treatment of Patients with Multiple Organ Dysfunction Syndrome

Overview

Journal Braz J Med Biol Res

Specialties Biology
General Medicine

Date 2017 Nov 30

PMID 29185591

Authors

B Tuerdi

L Zuo

H Sun

K Wang

Z Wang

G Li

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to discuss the safety and efficacy of regional citrate anticoagulation (RCA) on continuous blood purification (CBP) during the treatment of multiple organ dysfunction syndrome (MODS). Thirty-five patients with MODS were divided into two groups: the local citrate anticoagulation (RCA) group, and the heparin-free blood purification (hfBP) group. The MODS severity was assessed according to Marshall's MODS score criteria. Blood coagulation indicators, blood pressure, filter lifespan, filter replacement frequency, anticoagulation indicators, and main metabolic and electrolyte indicators were analyzed and compared between RCA and hfBP groups. RCA resulted in lower blood pressure than hfBP. The filter efficacy in RCA treatment was longer than in the hfBP group. The blood clearance of creatine, blood urea nitrogen and uric acid was better in the RCA group. RCA also led to higher pH than hfBP. Neither treatment resulted in severe bleeding events. In addition, MODS score was positively correlated with prothrombin time and activated partial thromboplastin time but negatively correlated with platelet concentration. RCA is a safer and more effective method in CBP treatment; however, it could also lead to low blood pressure and blood alkalosis.

References

Amanzadeh J, Reilly Jr R . Anticoagulation and continuous renal replacement therapy. Semin Dial. 2006; 19(4):311-6. DOI: 10.1111/j.1525-139X.2006.00178.x. View

Kung H, Hoyert D, Xu J, Murphy S . Deaths: final data for 2005. Natl Vital Stat Rep. 2008; 56(10):1-120. View

Kochanek K, Murphy S, Anderson R, Scott C . Deaths: final data for 2002. Natl Vital Stat Rep. 2004; 53(5):1-115. View

Tan H, Yang W, Chow P, Lui H, Choong H, Wong K . Anticoagulation minimization is safe and effective in albumin liver dialysis using the molecular adsorbent recirculating system. Artif Organs. 2007; 31(3):193-9. DOI: 10.1111/j.1525-1594.2007.00364.x. View

Oudemans-van Straaten H . Citrate anticoagulation for continuous renal replacement therapy in the critically ill. Blood Purif. 2010; 29(2):191-6. DOI: 10.1159/000245646. View

Onishi S, Yoshino S . Cathartic-induced fatal hypermagnesemia in the elderly. Intern Med. 2006; 45(4):207-10. DOI: 10.2169/internalmedicine.45.1482. View

Hetzel G, Schmitz M, Wissing H, Ries W, Schott G, Heering P . Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant. 2010; 26(1):232-9. DOI: 10.1093/ndt/gfq575. View

Slowinski T, Morgera S, Joannidis M, Henneberg T, Stocker R, Helset E . Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care. 2015; 19:349. PMC: 4587580. DOI: 10.1186/s13054-015-1066-7. View

Rico M, Fernandez Sarmiento J, Velasquez A, Gonzalez Chaparro L, Amaya R, Hoyos H . Regional citrate anticoagulation for continuous renal replacement therapy in children. Pediatr Nephrol. 2016; 32(4):703-711. DOI: 10.1007/s00467-016-3544-9. View

10.

Berbece A, Richardson R . Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal. Kidney Int. 2006; 70(5):963-8. DOI: 10.1038/sj.ki.5001700. View

11.

Xing R, Jin Y, Sun L, Yang L, Li C, Li Z . Interleukin-21 induces migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Clin Exp Immunol. 2015; 184(2):147-58. PMC: 4837236. DOI: 10.1111/cei.12751. View

12.

Kumar V, Craig M, Depner T, Yeun J . Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis. 2000; 36(2):294-300. DOI: 10.1053/ajkd.2000.8973. View

13.

Walsh C . Multiple organ dysfunction syndrome after multiple trauma. Orthop Nurs. 2005; 24(5):324-33. DOI: 10.1097/00006416-200509000-00006. View

14.

Cader R, Gafor H, Mohd R, Kong W, Arshad N, Kong N . Coupled Plasma Filtration and Adsorption (CPFA): A Single Center Experience. Nephrourol Mon. 2013; 5(4):891-6. PMC: 3842560. DOI: 10.5812/numonthly.11904. View

15.

Pannu N, Gibney R . Renal replacement therapy in the intensive care unit. Ther Clin Risk Manag. 2008; 1(2):141-50. PMC: 1661614. DOI: 10.2147/tcrm.1.2.141.62908. View

16.

Zaloga G . Hypocalcemia in critically ill patients. Crit Care Med. 1992; 20(2):251-62. DOI: 10.1097/00003246-199202000-00014. View

17.

Palsson R, Niles J . Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int. 1999; 55(5):1991-7. DOI: 10.1046/j.1523-1755.1999.00444.x. View

18.

Monchi M, Berghmans D, Ledoux D, Canivet J, Dubois B, Damas P . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2003; 30(2):260-265. DOI: 10.1007/s00134-003-2047-x. View

19.

Gasparovic V, Filipovic-Grcic I, Merkler M, Pisl Z . Continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD)--what is the procedure of choice in critically ill patients?. Ren Fail. 2003; 25(5):855-62. DOI: 10.1081/jdi-120024300. View

20.

Kielstein J, Kretschmer U, Ernst T, Hafer C, Bahr M, Haller H . Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis. 2004; 43(2):342-9. DOI: 10.1053/j.ajkd.2003.10.021. View